Procysbi 25 mg (Cysteamine (Cysteamine Bitartrate) CAPSULE (DELAYED RELEASE)) 25 MG

PROCYSBI 25 MG capsules are a delayed-release form of cysteamine bitartrate, used to manage certain metabolic conditions. This medication helps the body process specific substances more effectively.

Strength

25 MG

Manufacturer / TM Owner

AMGEN CANADA INC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

PROCYSBI 25 MG is primarily used to treat conditions related to the body's inability to process certain amino acids. Cysteamine bitartrate, the active ingredient, helps break down these substances, aiding in their elimination from the body. This medication is often prescribed for long-term management of these metabolic disorders.

Side Effects

Common effects of PROCYSBI 25 MG may include gastrointestinal discomfort, such as nausea or vomiting. Some users might experience changes in appetite or body odor. These effects can vary and are not experienced by everyone.

Precautions & Warnings

PROCYSBI 25 MG should be handled with care, as the capsules contain delayed-release beads that should not be crushed or chewed. It is important to follow the prescribed dosage and administration instructions provided by a healthcare professional. Store the medication in a cool, dry place away from direct sunlight.

Avoid Interactions

PROCYSBI 25 MG may interact with certain medications, including those that affect the stomach's acidity. It is advisable to consult a healthcare professional before taking this medication with other drugs, especially those that might alter its absorption or effectiveness.

References

Frequently Asked Questions

PROCYSBI 25 MG is used to manage certain metabolic conditions by helping the body process specific amino acids.

PROCYSBI 25 MG should be taken orally, with the capsules swallowed whole to avoid damaging the delayed-release beads.

Common side effects may include gastrointestinal discomfort, changes in appetite, and body odor.

It is important to consult a healthcare professional before taking PROCYSBI 25 MG with other medications to avoid potential interactions.

PROCYSBI 25 MG should be stored in a cool, dry place away from direct sunlight and out of reach of children.

Published by GNH India Pharmaceuticals Limited

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.